Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Amy Meng"'
Autor:
Amy Meng-Wen Pan, 孫孟文
91
This paper investigates the empirical determinants of corporate debt maturity structure by exploring the possible relations between the firm’s debt maturity structure and six firm-specific characteristics of agency-related costs, size, sign
This paper investigates the empirical determinants of corporate debt maturity structure by exploring the possible relations between the firm’s debt maturity structure and six firm-specific characteristics of agency-related costs, size, sign
Externí odkaz:
http://ndltd.ncl.edu.tw/handle/11790636615906501092
Autor:
Julie A Di Paolo, Amy Meng, Bernard Murray, Paqui G. Través, Federico Campigotto, René Galien
Publikováno v:
Annals of the Rheumatic Diseases
ObjectiveJanus kinase inhibitors (JAKinibs) are efficacious in rheumatoid arthritis (RA) with variable reported rates of adverse events, potentially related to differential JAK family member selectivity. Filgotinib was compared with baricitinib, tofa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3e2584ca5fa719702f7eec30d7c281
http://europepmc.org/articles/PMC8237188
http://europepmc.org/articles/PMC8237188
Autor:
孫孟文, Amy Meng-Wen Pan
本論文探討公司負債到期結構的實證決定因素。本研究首先選取台灣一般製造業104家樣本，使用複迴歸進行分析，結果顯示此104家樣本公司市價對帳面價值比與實質稅率的係數估計值為負，
Externí odkaz:
http://thesis.lib.nccu.edu.tw/cgi-bin/cdrfb3/gsweb.cgi?o=dstdcdr&i=sid=%22G0089932129%22.
Autor:
Amy Meng, Kacey Anderson, Cara Nelson, Liyun Ni, Shu-Min Chuang, Francesco Bellanti, Peter Chang, Craig Comisar, Brian Kearney, Beatrix Bartok, Anita Mathias
Aims:Filgotinib is a potent, oral, JAK1-preferential inhibitor for the treatment of rheumatoid arthritis (RA). This report describes exposure-response (ER) analyses of filgotinib for dose confirmation based on three Phase 3 and two Phase 2 studies in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3181fd74a0c16d42554a0cd43ab9443f
https://doi.org/10.22541/au.162418885.56100410/v1
https://doi.org/10.22541/au.162418885.56100410/v1
Autor:
Chia-Hsiang Hsueh, Ethan Grant, Helen Yu, Thomas Tarnowski, Rita Humeniuk, Franziska Matzkies, Cara H. Nelson, Amy Meng, Ellen Kwan, Andrew N. Billin, Joy Y. Feng, Hoa Truong, Juliane M. Jürgensmeier
Publikováno v:
Clinical pharmacology and therapeutics. 111(2)
Tirabrutinib is an irreversible, small-molecule Bruton's tyrosine kinase (BTK) inhibitor, which was approved in Japan (VELEXBRU) to treat B-cell malignancies and is in clinical development for inflammatory diseases. As an application of model-informe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f84cc09f82f56411422cf6ad746feba
https://pubmed.ncbi.nlm.nih.gov/34623640
https://pubmed.ncbi.nlm.nih.gov/34623640
Autor:
Shariq Haider, Edward Gane, Jose Luis Calleja, Rafael Esteban, Svetlana Markova, Kosh Agarwal, Rafael Bruck, Amy Meng, Stephen D. Shafran, Sergio Borgia, Matthew Foxton, Robert H. Hyland, Javier Ampuero, Bernard Willems, Anu Osinusi, Raymond Fox, David R. Shaw, Conrado M Fernández Rodríguez, Ziv Ben-Ari, Hadas Dvory-Sobol, Ashley Brown, Stephen D. Ryder, Curtis Cooper, Matthew E. Cramp, Brian J. Kirby, Eric M. Yoshida, Yoav Lurie, Sophia Lu, Janet Dearden
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
[Background & Aims] Although off-label use of sofosbuvir-containing regimens occurs regularly in patients with hepatitis C virus (HCV) infection undergoing dialysis for severe renal impairment or end-stage renal disease (ESRD), these regimens are not
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fde6a1aadbb3d654fea75498b360a160
https://hdl.handle.net/10668/14107
https://hdl.handle.net/10668/14107
Autor:
Amy Meng, Rebecca Begley, Jiang Shao, John Ling, Benedetta Massetto, Christina Sze Man Yip, Anita Mathias
Publikováno v:
Clinical Hepatology.
Background SOF 400 mg and LDV/SOF 90/400 mg are approved HCV treatment in adults and adolescents. Pharmacokinetic (PK) data indicates that SOF 200 mg and LDV/SOF 45/200 mg are appropriate doses in children 6 to Methods HCV-infected children (3 to Res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1cc609c352c994fd825df0b372bf95da
https://doi.org/10.1136/gutjnl-2019-iddfabstracts.269
https://doi.org/10.1136/gutjnl-2019-iddfabstracts.269
Publikováno v:
Poster Presentations.
Background Inhibition of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway has demonstrated efficacy in immune-mediated diseases and has been identified as a therapeutic target for the treatment of rheumatoid arth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::44bff10c4b5b0e72e8c57748a1125296
https://doi.org/10.1136/annrheumdis-2019-eular.3361
https://doi.org/10.1136/annrheumdis-2019-eular.3361
Autor:
L. Simpson, G. Min-Oo, E. Grant, J. A. Di Paolo, P. Gonzalez-Traves, Bernard P. Murray, Amy Meng
Publikováno v:
Annals of the Rheumatic Diseases. 80:331.1-331
Background:Janus kinase (JAK) inhibitors (JAKinibs) show similar efficacy in rheumatoid arthritis (RA). However, in vitro studies have shown differences in JAK selectivity profiles for baricitinib (BARI), tofacitinib (TOFA), upadacitinib (UPA) and fi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abea34200585e7a24f14a828cbe93313
https://doi.org/10.1136/annrheumdis-2021-eular.2741
https://doi.org/10.1136/annrheumdis-2021-eular.2741
Publikováno v:
Journal of the American Society for Mass Spectrometry. 27:1277-1284
In this study, we report on the use of differential mobility spectrometry (DMS) as a tool for studying tautomeric species, allowing a more in-depth interrogation of these elusive isomers using ion/molecule reactions and tandem mass spectrometry. As a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6b62fdab973388051e5efa8d33a161bd
https://doi.org/10.1007/s13361-016-1392-2
https://doi.org/10.1007/s13361-016-1392-2